Abstract
Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2% of synovial sarcomas, 67.7% of myxoid liposarcomas, 43.8% of osteosarcomas, 41.4% of angiosarcomas, 24.6% of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4% of chondrosarcomas. NY-ESO-1 expression was found in 88.2% of myxoid liposarcomas, 61.1% of synovial sarcomas, 31.3% of osteosarcomas, 21.4% of pleomorphic liposarcomas, 16.7% of desmoplastic small round cell tumors, and 14.3% of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.
Similar content being viewed by others
References
Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B (2003) Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 4:104–109
Ikeda H, Lethé B, Lehmann F, van Baren JF, Baurain JF, de Smet C et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208
Duffour MT, Chaux P, Lurquin C, Cornelis GBT (1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 29:3329–3337
Shafer J, Cruz C, Leen A, Ku S, Lu A, Rousseau A et al (2011) Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma 51:870–880
Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y et al (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 103:150–153
Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E et al (2014) High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32:5901–5907
Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K et al (2015) Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21:2268–2277
Resnick MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E (2002) Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer 101:190–195
Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E et al (2002) Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100:702–705
Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M et al (2003) Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 64:443–449
Bandić D, Juretić A, Sarcević B, Separovic V, Kujundzic-Tiljak M, Hudolin T et al (2006) Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 47:32–41
Montoro JR, Mamede RC, Neder Serafini L, Saggioro FP, Figueiredo DL, Silva WA Jr et al (2012) Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head Neck 34:1123–1128
Jäger BE, Chen Y, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al (1998) Simultaneous humoral and cellular immune response against cancer–testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924
Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P et al (2011) Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 6:e17876. doi:10.1371/journal.pone.0017876
Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, Oneill D et al (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)—correlation with prognostic factors. Cancer Immun 7:11
Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A et al (2001) NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade advances in brief NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade 1. Cancer Res 61:4671–4674
Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M et al (2014) Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer 135:1142–1152
John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC et al (2013) The role of cancer-testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One 8:e67876. doi:10.1371/journal.pone.0067876
Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H et al (2016) Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4 and MAGEA1. Hum pathol. doi:10.1016/j.humpath.2016.12.006
Lai J-P, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA et al (2012) NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 25:854–858
Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH et al (2014) NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28:587–595
Christopher DMF, Julia AB, Pancras CW, Hogendoorn FM (2013) WHO classification of tumor of oft tissue and bone, 4th edn. Int Agency Res Cancer, Lyon, pp 33–43
Cabezon T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N et al (2012) Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics 12:381–394
Iura K, Kohashi K, Hotokebuchi Y, Ishii T, Maekawa A, Yamada Y et al (2015) Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 1:144–159
Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E et al (2012) Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118:3330–3336
Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ et al (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120:67–74
Zou C, Shen J, Tang Q, Yang Z, Yin J, Xie X et al (2012) Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer 118:1845–1855
Boring CC, Squires TS, Tong T (1993) Cancer statistics, 1993. CA Cancer J Clin 43:7–26
Lin C, Mak S, Meitner PA, Wolf JM, Bluman EM, Block JA et al (2002) Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. Gene 285:269–278
Hruban RH, Shiu MH, Senie RT, Woodruff JM (1990) Malignant peripheral nerve sheath tumors of the buttock and lower extremity. Cancer 66:1253–1265
Nobeyama Y, Nakagawa H (2016) Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. J Dermatol Sci 81:118–123
Dufresne A, Cassier P, Couraud L, Marec-Berard P, Meeus P, Alberti L et al (2012) Desmoplastic small round cell tumor: current management and recent findings. Sarcoma. doi:10.1155/2012/714986
Acknowledgments
We thank the Research Support Center, Graduate School of Medical Sciences, Kyushu University for the technical support. We also thank KN International for revising the English usage.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was approved the Ethics Committee of Kyushu University (No. 26-49) and conducted according to the principles embodied in the Declaration of Helsinki. Informed consent was obtained from the subjects or guardians.
Funding
This study was supported by a JSPS KAKEN Grant (No. 25293088) and by funds from the Scholarship Program of the Takeda Science Foundation.
Conflict of interest
The authors declare that they have no conflicts of interest.
Electronic supplementary material
Supplementary Table 1
(DOCX 19 kb)
Supplementary Table 2
(DOCX 18 kb)
Rights and permissions
About this article
Cite this article
Iura, K., Kohashi, K., Ishii, T. et al. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1. Virchows Arch 471, 383–392 (2017). https://doi.org/10.1007/s00428-017-2206-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-017-2206-z